Literature DB >> 2333468

Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin.

A D Wilson1, C J Clarke, C R Stokes.   

Abstract

Cholera toxin (CT) is a potent stimulator of IgA responses when administered orally and has been shown to promote IgA responses to a second protein such as keyhole limpet haemocyanin (KLH) if this is fed simultaneously. In this paper we show that whilst feeding 5 mg KLH with either 0.5 micrograms CT or 10 micrograms B subunit fails to stimulate a mucosal IgA response to KLH, feeding 0.5 microgram CT and 10 micrograms B subunit together with 5 mg KLH produces a local IgA anti-KLH response as great as that produced by 10 micrograms of whole CT. In addition to stimulating IgA responses in the lamina propria, preliminary results indicate that cellular responses are also stimulated, as we have demonstrated KLH antigen-driven proliferation of cells isolated from groups of mice fed either 10 micrograms CT + 5 mg KLH or 0.5 micrograms CT + 10 micrograms CTB + 5 mg KLH but not mice fed KLH alone or with either 10 micrograms CTB or 0.5 micrograms CT. These results indicate that the mucosal adjuvant action of CT is due to a synergistic effect involving both the GM1 binding of the B subunit and adenylate cyclase activation by the A subunit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333468     DOI: 10.1111/j.1365-3083.1990.tb02791.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  Involvement of antigen-presenting cells in the enhancement of the in vitro antibody responses by cholera toxin B subunit.

Authors:  Y Hirabayashi; S I Tamura; K Shimada; T Kurata
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

Review 2.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant.

Authors:  C J Clarke; A D Wilson; N A Williams; C R Stokes
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

4.  Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit.

Authors:  M W Russell; H Y Wu
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Primary antigen-specific T-cell proliferative responses following presentation of soluble protein antigen by cells from the murine small intestine.

Authors:  N A Williams; A D Wilson; M Bailey; P W Bland; C R Stokes
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

7.  Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.

Authors:  N Toida; G Hajishengallis; H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

8.  Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin.

Authors:  L de Haan; W R Verweij; I K Feil; T H Lijnema; W G Hol; E Agsteribbe; J Wilschut
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

9.  Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.

Authors:  A Lee; M Chen
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.